Diagnosis of medullary thyroid carcinoma by calcitonin measurement in fine-needle aspiration biopsy specimens

被引:69
作者
Kudo, Takumi
Miyauchi, Akira
Ito, Yasuhiro
Takamura, Yuuki
Amino, Nobuyuki
Hirokawa, Mitsuhiro
机构
[1] Kuma Hosp, Dept Surg, Chuo Ku, Kobe, Hyogo 6500011, Japan
[2] Kuma Hosp, Dept Internal Med, Chuo Ku, Kobe, Hyogo 6500011, Japan
[3] Kuma Hosp, Dept Pathol, Chuo Ku, Kobe, Hyogo 6500011, Japan
关键词
D O I
10.1089/thy.2006.0338
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Medullary thyroid carcinoma (MTC) is a thyroid malignancy originating from C cells. To date, serum calcitonin measurement and fine-needle aspiration biopsy (FNAB) have been prominent diagnostic approaches to these lesions. Although an elevated serum calcitonin level strongly suggests the presence of MTC, this examination cannot identify the origin of the calcitonin overexpression, especially in patients demonstrating multiple thyroid nodules. For the treatment planning, it is important to know which nodule is MTC, especially in nonhereditary MTC. In this study, we propose calcitonin measurement in the washout of FNAB needles after sampling each tumor (FNAB-CT) as a new approach to diagnosis of MTC. We performed FNAB-CT for five MTC cases. Although only one of these cases was definitively diagnosed as having MTC by FNAB cytology, FNAB-CT values ranged from 17,000 to 560,000 pg/mL, which were exceedingly higher than those of 11 controls (seven papillary carcinomas, two adenomatous nodules, one chronic thyroiditis, and one normal thyroid), which showed values ranging from <10 to 67 pg/mL. In patients with MTC, FNAB-CT values were 74 to 1888 times greater than serum calcitonin values. These findings suggest that FNAB-CT can be an additional approach to diagnosis of MTC.
引用
收藏
页码:635 / 638
页数:4
相关论文
共 14 条
[1]
BALL DW, 2001, THYROID, P930
[2]
Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumors [J].
Baudin, E ;
Bidart, JM ;
Rougier, P ;
Lazar, V ;
Ruffié, P ;
Ropers, J ;
Ducreux, M ;
Troalen, F ;
Sabourin, JC ;
Comoy, E ;
Lasser, P ;
DeBaere, T ;
Schlumberger, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (01) :69-75
[3]
Preoperative diagnosis of medullary thyroid carcinoma: Fine needle aspiration cytology as compared with serum calcitonin measurement [J].
Bugalho, MJM ;
Santos, JR ;
Sobrinho, L .
JOURNAL OF SURGICAL ONCOLOGY, 2005, 91 (01) :56-60
[4]
COLLINS BT, 1995, ACTA CYTOL, V39, P920
[5]
Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: Experience in 10,864 patients with nodular thyroid disorders [J].
Elisei, R ;
Bottici, V ;
Luchetti, F ;
Di Coscio, G ;
Romei, C ;
Grasso, L ;
Miccoli, P ;
Iacconi, P ;
Basolo, F ;
Pinchera, A ;
Pacini, F .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (01) :163-168
[6]
Central neck dissection in the management of sporadic medullary thyroid microcarcinoma [J].
Hamy, A ;
Pessaux, P ;
Mirallié, E ;
Mucci-Hennekinne, S ;
Gibelin, H ;
Mor-Martinez, C ;
de Calan, L ;
Ronceray, J ;
Kraimps, JL .
EJSO, 2005, 31 (07) :774-777
[7]
RET proto-oncogene:: A review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors [J].
Kouvaraki, MA ;
Shapiro, SE ;
Perrier, ND ;
Cote, GJ ;
Gagel, RF ;
Hoff, AO ;
Sherman, SI ;
Lee, JE ;
Evans, DB .
THYROID, 2005, 15 (06) :531-544
[8]
Unilateral surgery supported by germline RET oncogene mutation analysis in patients with sporadic medullary thyroid carcinoma [J].
Miyauchi, A ;
Matsuzuka, F ;
Hirai, K ;
Yokozawa, T ;
Kobayashi, K ;
Kuma, S ;
Kuma, K ;
Futami, H ;
Yamaguchi, K .
WORLD JOURNAL OF SURGERY, 2000, 24 (11) :1367-1372
[9]
Niccoli P, 1996, ANN ENDOCRINOL-PARIS, V57, P15
[10]
Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses [J].
Redding, AH ;
Levine, SN ;
Fowler, MR .
THYROID, 2000, 10 (10) :919-922